Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Johannes Drach, Huiqiang Huang, Olga Samoilova, Andrew Belch, Charles Farber, André Bosly, Jan Novak, Jan Zaucha, Angela Dascalescu, Udomsak Bunworasate, Zvenyslava Masliak, Kateryna Vilchevskaya, Tadeusz Robak, Lixia Pei, Brendan Rooney, Helgi van de Velde & Franco Cavalli. (2018) Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Leukemia & Lymphoma 59:4, pages 896-903.
Read now
Read now
Leo I. Gordon, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas E. Witzig & Martin Dreyling. (2014) Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma 55:10, pages 2262-2270.
Read now
Read now
Andre Goy. (2013) Mantle cell lymphoma: continuously improving the odds!. Expert Opinion on Orphan Drugs 1:12, pages 1001-1018.
Read now
Read now
Peter H Wiernik. (2013)
Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 14:4, pages 475-488.
Read now
Read now
Articles from other publishers (28)
Noa Biran,Pooja Phull,andand & Andre Goy. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
331
360
.
Francis R. LeBlanc, Zainul S. Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V. Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M. Martin, Mark Kester, Todd Fox, Jiangang Liao, Thomas P. Loughran, Juanita Evans, Jeffrey J. Pu, Stephen E. Spurgeon, Mirit I. Aladjem & Elliot M. Epner. (2022) Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget 13:1, pages 986-1002.
Crossref
Crossref
Jeffrey J. Pu, Malvi Savani, Nick Huang & Elliot M. Epner. (2022) Mantle cell lymphoma management trends and novel agents: where are we going?. Therapeutic Advances in Hematology 13, pages 204062072210807.
Crossref
Crossref
Tao Wang, Wenqin Yue, Gusheng Tang, Mingyu Ye, Jiechen Yu, Bin Liu, Lijuan Jiao, Xuefei Liu, Shuyi Yin, Jie Chen, Lei Gao, Jianmin Yang & Miaoxia He. (2021) SAMHD1 Mutations and Expression in Mantle Cell Lymphoma Patients. Frontiers in Oncology 11.
Crossref
Crossref
Jessalyn A. Weaver, Yi Peng, Yuanyuan Ji, David Gilbertson, Daniel F. Pease & Vicki A. Morrison. (2021) A medicare database analysis of practice patterns in patients with mantle cell lymphoma. Journal of Geriatric Oncology 12:6, pages 894-901.
Crossref
Crossref
Michael J. Buege, Anita Kumar, Brianne N. Dixon, Laura A. Tang, Terry Pak, Jennifer Orozco, Tim J. Peterson & Kathryn T. Maples. (2020) Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy 54:9, pages 879-898.
Crossref
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2020) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 153, pages 103038.
Crossref
Crossref
Stephen E. Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, YiYi Chen, Motomi Mori, Zainul Hasanali & Elliot M. Epner. (2019) Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology 186:6, pages 845-854.
Crossref
Crossref
Pamela McKay, Mike Leach, Bob Jackson, Stephen Robinson & Simon Rule. (2018) Guideline for the management of mantle cell lymphoma. British Journal of Haematology 182:1, pages 46-62.
Crossref
Crossref
Daniel F. Pease & Vicki A. Morrison. (2018) Treatment of mantle cell lymphoma in older adults. Journal of Geriatric Oncology 9:4, pages 308-314.
Crossref
Crossref
Soham D. Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan & Daniel O. Persky. (2018) Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Clinical Lymphoma Myeloma and Leukemia 18:1, pages 58-64.
Crossref
Crossref
Vijaya Raj Bhatt, Roberto Ferro Valdes & Julie M. Vose. 2018. Hematology. Hematology
1298
1308.e2
.
Stephen E. Spurgeon, Brian G. Till, Peter Martin, Andre H. Goy, Martin P. Dreyling, Ajay K. Gopal, Michael LeBlanc, John P. Leonard, Jonathan W. Friedberg, Lawrence Baizer, Richard F. Little, Brad S. Kahl & Mitchell R. Smith. (2016) Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute 109:1, pages djw263.
Crossref
Crossref
Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, Norbert Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, Lars Hahn, Julia Vereshchagina, Frank Kauff, Wolfgang Blau, Axel Hinke & Juergen Barth. (2016) Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology 17:1, pages 57-66.
Crossref
Crossref
Babak Rajabi & John W. Sweetenham. (2014) Mantle cell lymphoma: observation to transplantation. Therapeutic Advances in Hematology 6:1, pages 37-48.
Crossref
Crossref
Xiaoshen Sun, Zainul S. Hasanali, Allshine Chen, Dianzheng Zhang, Xin Liu, Hong-Gang Wang, David J. Feith, Thomas P. LoughranJrJr & Kailin Xu. (2015) Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. British Journal of Haematology 168:3, pages 371-383.
Crossref
Crossref
Annete Njue, Ann Colosia, Peter C. Trask, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Police, Jianmin Wang, Rodrigo Ruiz-Soto, James A. Kaye & Farrukh Awan. (2015) Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma Myeloma and Leukemia 15:1, pages 1-12.e7.
Crossref
Crossref
D.J. Inwards, P.A. Fishkin, B.R. LaPlant, M.T. Drake, P.J. Kurtin, D.A. Nikcevich, D.B. Wender, B.S. Lair & T.E. Witzig. (2014) Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annals of Oncology 25:10, pages 2020-2024.
Crossref
Crossref
Tiffany Tang & Peter Martin. (2014) Mantle Cell Lymphoma: Taking Therapeutic Advantage of New Insights into the Biology. Current Hematologic Malignancy Reports 9:3, pages 254-261.
Crossref
Crossref
Eva HosterWolfram KlapperOlivier HermineHanneke C. Kluin-NelemansJan WalewskiAchiel van HoofMarek TrnenyChristian H. GeislerFrancesco Di RaimondoMichal SzymczykStephan StilgenbauerCatherine ThieblemontMichael HallekRoswitha ForstpointnerChristiane PottVincent RibragJeanette DoorduijnWolfgang HiddemannMartin H. DreylingMichael Unterhalt. (2014) Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology 32:13, pages 1338-1346.
Crossref
Crossref
Antonino Carbone & Anas YounesKathrin Aprile von HohenstaufenAlden MocciaEmanuele Zucca. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies
232
249
.
Jan Walewski. (2013) Chłoniak z komórek płaszcza u pacjentów niekwalifikujących się do chemioterapii w wysokich dawkach. Acta Haematologica Polonica 44:2, pages 104-109.
Crossref
Crossref
Vikas Ghai, Kamal Sharma, Kamal K. S. Abbi, Sara Shimko & Elliot M. Epner. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy
257
266
.
Zainul Hasanali, August Stuart, Nelson Yee, Kamal Sharma & Elliot Epner. (2012) The Epigenetics of Gastrointestinal Malignancies. Current Colorectal Cancer Reports 8:4, pages 254-262.
Crossref
Crossref
P. McKay, M. Leach, R. Jackson, G. Cook & S. Rule. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology 159:4, pages 405-426.
Crossref
Crossref
Monika Joshi, Hassan Sheikh, Kamal Abbi, Sarah Long, Kamal Sharma, Mark Tulchinsky & Elliot Epner. (2012) Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Therapeutic Advances in Hematology 3:5, pages 275-290.
Crossref
Crossref
Bijal D. Shah, Peter MartinEduardo M. Sotomayor. (2012) Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches. Cancer Control 19:3, pages 227-235.
Crossref
Crossref
Zainul Hasanali, Kamal Sharma & Elliot Epner. (2012) Flipping the cyclin D1 switch in mantle cell lymphoma. Best Practice & Research Clinical Haematology 25:2, pages 143-152.
Crossref
Crossref